Neuroscience

PaxMedica Appoints David Hough M.D. as Chief Medical Officer

Announces Additional Management Changes; Independent Directors Now Majority of Board TARRYTOWN, NY, Aug. 16, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire…

11 months ago

Strathspey Crown Holdings Group, LLC Provides Clarifying Statement Regarding Form 4 Filing with SEC for Holdings in AEON Biopharma

The 7,380,394 AEON shares reflected in the Form 4 filed on August 14th were transferred to limited partners of Strathspey Crown Strathspey Crown did…

11 months ago

Amicus Therapeutics Announces Approval and Launch of New Pompe Disease Therapy in the United Kingdom

Pombiliti® (cipaglucosidase alfa) + Opfolda® (miglustat) Approved for Adults Living with Late-Onset Pompe Disease in Great Britain National Institute for…

11 months ago

Neuronetics Revolutionizes Patient Communication and Provider Support Through Its Exclusive TrakStar® Platform

New automated features elevate the standard of care for NeuroStar® Advanced Therapy practicesMALVERN, Pa., Aug. 14, 2023 (GLOBE NEWSWIRE) --…

11 months ago

Vaxxinity Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer’s Disease

Phase 2a data published in The Lancet’s eBioMedicine supports further development of UB-311 The paper concludes that UB-311 is the…

11 months ago

Neuronetics Reports Record Second Quarter 2023 Financial and Operating Results

MALVERN, Pa., Aug. 08, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology…

11 months ago

Cognition Therapeutics Reports Second Quarter 2023 Financial Results and Business Update

Announced Positive Topline Results from CT1812 Phase 2 SEQUEL Study in Mild-to-Moderate Alzheimer’s Disease Commenced Recruitment for 540-patient Phase 2…

11 months ago

Arvinas Reports Second Quarter 2023 Financial Results and Provides Corporate Update

– Enrollment continues globally in multiple clinical studies of vepdegestrant (ARV-471), including VERITAC-2 2L Phase 3 trial and study lead-in…

11 months ago

New Study Finds That Masimo SedLine® Patient State Index (PSi) Has the Potential to Improve Brain Monitoring for Patients Sedated with Dexmedetomidine

Masimo PSi, a Processed EEG Parameter, “Better Captured” Changes in Brain State Compared to Other Assessment MethodsIRVINE, Calif.--(BUSINESS WIRE)--Masimo (NASDAQ:…

11 months ago

Akoya Biosciences Announces Milestone of 1,000 Peer-Reviewed Publications Citing Use of its Spatial Biology Technologies

MARLBOROUGH, Mass., Aug. 07, 2023 (GLOBE NEWSWIRE) -- Akoya Biosciences , Inc. (Nasqad: AKYA)(“Akoya), The Spatial Biology Company®, today announced…

11 months ago